Merck Vioxx News and Press Releases

CHAPEL HILL, N.C., Feb. 23 /PRNewswire/ -- After an FDA panel recently recommended that Vioxx could return to the marketplace, investors pushed Merck's stock up 13%. The reason for investor optimism is that this recommendation may limit Merck's legal liability, estimated at as much as $20 billion.

Even though Merck may have dodged a legal liability bullet, it still will take a large hit to future revenue because of the negative publicity. Better communicating Vioxx's clinical trial results and indicating potential cardiovascular problems earlier could have avoided the negative fallout from the voluntary recall.

With the question of Cox-2 inhibitor's efficacy still unresolved, how can pharmaceutical companies better communicate the results of their clinical trials? Research from Best Practices, LLC reveals that best-in-class companies understand that successfully communicating landmark trial results begins long before significant findings are available. Successful communication depends on early actions across the board including:

- Early identification of breakthrough molecules in development - Early creation of potential product positioning - Early involvement of marketing to build commercial endpoints into the study design

- Early scenario planning for different study results

Best Practices, LLC has a ready-to-implement checklist that illustrates Best Practices in Communicating Clinical Trial Results: Overview & Lessons Learned, For more information, visit http://www3.best-in-class.com/dr132.htm to purchase this and related research.

Companies must keep sight of the goal when communicating clinical trial results -- accelerating adoption of the drug. All activities in the communication plan must tie back to this goal, explains one pharmaceutical executive. He builds his communication plans around what he calls the "Five Ps of Acceleration."

* Position: The positioning process before a trial begins by ensuring that the study will generate data necessary to support product positioning. The company then further positions the trial and results as a landmark study for maximum exposure.
* Publish: Focus on honest communication of study results through peer reviewed journals.
* Present: Use scientific experts to conduct a "road show" that shares results with physician and managed care audiences.
* Promote: Promotion revolves around the marketing team activities for communicating the study results. A successful communication plan allows a study to "take on a life of its own."
* Penetrate: Take advantage of as many communication channels as possible to disseminate results

Visit http://www3.best-in-class.com/dr132.htm to learn more or purchase Best Practices in Communicating Clinical Trial Results: Overview & Lessons Learned and to download a complimentary sample on clinical trial excellence. For more information about this or other benchmarking reports, contact Tracy Hollister at (919) 767-9225 or at thollister@best-in-class.com .

ABOUT BEST PRACTICES, LLC

Best Practices, LLC bases its benchmarking work on the simple yet profound principle that organizations can attain superior economic performance by studying and implementing the best business practices, operating tactics, and winning strategies of excellent companies. Best Practices' industry specializations include pharmaceuticals, financial services, telecommunications, media, and utilities. Visit the corporate website at http://www.best-in-class.com .

Source: Best Practices, LLC

By Susan Heavey

WASHINGTON, Feb 14 (Reuters) - A veteran scientist at the U.S. Food and Drug Administration said on Monday he had decided against presenting new data on the heart risk of pain relievers at a highly anticipated meeting later this week, saying he felt intimidated by FDA officials.

David Graham, associate director for science and medicine at the FDA's Office of Drug Safety, had planned to present the as-yet-unpublished information to a panel of health experts who will discuss safety issues with pain relievers like Merck & Co. Inc.'s <MRK.N> now withdrawn Vioxx.

The FDA called for the public meeting after several studies showed a link between some of the drugs and heart attacks or strokes. The experts will also discuss whether Pfizer Inc.'s <PFE.N> Celebrex and Bextra, drugs similar to Vioxx, should remain on the market.

But Graham told Reuters in an interview that an e-mail from his supervisor Paul Seligman said that if he continued to press for inclusion of the new data he would be doing so at his own risk. "The tone of it is (that) I'm being insubordinate," he said. An FDA spokeswoman said agency officials told Graham it was his choice as to whether he wanted to present. "We just prefer that published literature be presented," she said. But Graham said it was not a real choice. "Because I feel so threatened by management, it's not worth taking the risk," he said he told his supervisors.

The study in question examined data from California's Medicaid program, called Medi-Cal, and is larger than any previous related study and looked at more than 15,000 heart attack patients, Graham said. "Our findings are important to the safety of a number of marketed pain relievers," he said. The pain medicines, a type of non-steroidal anti-inflammatory drug (NSAID), are part of a class known as Cox-2 inhibitors.

At a congressional hearing in November, Graham testified about his worries over the agency's handling of drug safety. His testimony, which included warnings about other drugs he considered unsafe, caused the FDA to defend its drug approval process and raised concerns of public interest groups and others about whether the 20-year agency veteran would be fired or reassigned. "This is an instant replay," said Graham, who is scheduled to speak on the second day of the three-day meeting due to start on Wednesday.

Graham said managers had not "spoken to me to say 'your perception is wrong'" about the risk to his job or to encourage him to present the new findings. Sen. Charles Grassley, chairman of the Senate Finance Committee that held the November hearing, said the FDA first told Graham he could not present the study but later, in Seligman's e-mail, said it was Graham's decision to make. In part of the e-mail quoted by Grassley, Seligman said, "I think we've already articulated our preference that your talk cover the key studies in the published literature. Clearly, you would like to cover more than this which is your call." Grassley said Graham was "being sent mixed messages."

"Dr. Seligman is clearly saying to Dr. Graham proceed at your own risk," the Iowa Republican wrote in a letter to FDA Acting Commissioner Lester Crawford sent late Monday. Grassley also questioned the FDA's defense that only published studies should be presented, noting that Graham was reportedly asked to present information from an unpublished Merck study.

Other Resources
Drug Stores
Medical Classifieds
Legal Search Engine
Top Mesothelioma Sites
Phone Cards

Vioxx-Search-Engine.com
7141 Oak Pointe Curve
Minneapolis, MN 55438 USA

©Copyright
Nielsen Technical Services
All Rights Reserved Worldwide